UCL Launches Landmark Trial to Assess Impact of blood Test for Alzheimer’s Disease
University College London (UCL) has initiated teh ADAPT trial, a key component of the Blood Biomarker Challenge, focused on evaluating the real-world impact of a new blood test for Alzheimer’s disease. The trial,led by researchers at the UCL Queen Square Institute of Neurology,aims to demonstrate how the test can improve patient care and accelerate diagnosis.
Currently, only approximately 2% of individuals diagnosed with Alzheimer’s receive confirmation thru gold-standard diagnostic methods like PET scans and lumbar punctures - tests that are both costly and less accessible. The new blood test offers a comparable level of diagnostic data but is significantly more affordable and easier to administer.
Unlike previous research focused on the accuracy of the blood test – which has already been established – the ADAPT trial will specifically assess whether it’s implementation leads to earlier and more effective patient management. Researchers will index the impact of the test on onward care, hoping to demonstrate its ability to expedite diagnosis.
The potential for earlier, accurate diagnosis is notably crucial as new treatments emerge that aim to slow the progression of memory and thinking decline. Timely identification of Alzheimer’s will be vital to ensure these therapies reach those who need them most.
The importance of improved diagnosis was echoed by Alzheimer’s Society’s recent Lived Experience Survey, which revealed that only a third of people with dementia reported a positive diagnostic experience, with many expressing fear of receiving a diagnosis. This often results in delayed diagnoses,limiting access to vital support,treatment,and future planning opportunities.
Alzheimer’s Research UK, a partner in the Blood Biomarker Challenge, highlighted that currently one in three people with dementia remain undiagnosed. They emphasized the trial as a meaningful step towards transforming dementia diagnosis across the UK,demonstrating the benefits of sustained investment in research.
Michael White, 75, a member of the ADAPT Patient and Public involvement (PPI) group, shared his personal experience, noting that it took two and a half years to receive a diagnosis for his wife, Kathryn.He believes a blood test like this coudl have significantly shortened that timeframe and improved their experience.Kathryn White, 74, added that receiving a diagnosis, despite the initial difficulty, ultimately provided relief and helped them understand what was happening.
